Holen Sie sich die Stockscreener-App
1.315
0.38%
-0.00
Schlusskurs vom Vortag:
$1.315
Offen:
$1.3
24-Stunden-Volumen:
598.27K
Relative Volume:
0.22
Marktkapitalisierung:
$252.84M
Einnahmen:
$314.00K
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-4.6964
EPS:
-0.28
Netto-Cashflow:
$-84.71M
1W Leistung:
-10.88%
1M Leistung:
-15.76%
6M Leistung:
+12.93%
1J Leistung:
-47.81%
1-Tages-Spanne:
$1.25
$1.35
1-Wochen-Bereich:
$1.22
$1.48
52-Wochen-Spanne:
$1.03
$2.64
Atai Life Sciences N V Stock (ATAI) Company Profile
Firmenname
Atai Life Sciences N V
Sektor
Branche
Telefon
49 89 2153 9035
Adresse
WALLSTRASSE 16, BERLIN
Vergleichen Sie ATAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.315 | 252.84M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.07 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.05 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.87 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
248.79 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
243.33 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-03 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
| 2021-11-11 | Eingeleitet | ROTH Capital | Buy |
| 2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-01 | Eingeleitet | Jefferies | Buy |
| 2021-07-13 | Eingeleitet | Berenberg | Buy |
| 2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2021-07-13 | Eingeleitet | Citigroup | Buy |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Atai Life Sciences N V Aktie (ATAI) Neueste Nachrichten
Berenberg starts atai Life Sciences coverage with Positive rating - Investing.com
How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com Australia
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa
Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India
Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India
Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India
Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India
Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK
Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews
ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance
Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
How is ATAI’s stock performing after recent trades? - US Post News
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance UK
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com
atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK
Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Atai Life Sciences Prices $55 Million Stock Offering -February 13, 2025 at 04:47 am EST - Marketscreener.com
ATAI Life Sciences Secures Massive $55M War Chest for Breakthrough Mental Health Treatments - StockTitan
atai Life Sciences Announces Pricing of Public Offering of Common Shares - Yahoo Finance
atai Life Sciences unveils $55M public offering to advance mental health treatments - Proactive Investors USA
atai Life Sciences Secures Major Funding: $55M Share Offering to Revolutionize Mental Health Treatment Pipeline - StockTitan
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback (ATAI:NASDAQ) - Seeking Alpha
Evaluating ATAI’s financial ratios for a profitable investment - US Post News
Get in on ATAI Life Sciences N.V’s (ATAI) buy-in window today! - SETE News
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trialICYMI - Proactive Investors USA
ATAI Life Sciences N.V (NASDAQ: ATAI) Has Succeeded In Attracting Investors This Year, The Stock Is Up 59.40% Year-To-Date – Marketing Sentinel - Marketing Sentinel
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe - Proactive Investors USA
Finanzdaten der Atai Life Sciences N V-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):